Acute Ischemic Stroke
Conditions
Brief summary
The goal of this observational study is to learn about the long-term efficacy of our previous study in acute ischemic stroke(AIS) patients who underwent either remote ischemic postconditioning(RIPC) or sham treatment after intravenous thrombolysis. The main questions it aims to answer are: * Dose the RIPC treatment combined with IV thrombolysis can improve the long-term functional outcome in AIS patients? * Dose the RIPC treatment combined with IV thrombolysis can improve the incidence rates of all-cause and cardiovascular mortality, recurrent stroke/TIA, new-onset clinical AF on this long-term follow-up? A single rater (A.E.P.) trained by an experienced stroke physician (S.T.E.) contacted patients, relatives, and family physicians to gather all available medical information on the following issues: 1) survival status, 2) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy. Researchers will compare RIPC group and control group to see if the RIPC treatment have a long-term effect in AIS patients.
Interventions
OTHERfunctional and medical information
1\) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients who completed the previous interventional rater-blinded controlled study were invited for the follow-up session.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the proportion of excellent functional outcome, % | through study completion, an average of 5 year | An excellent functional outcome define as mRS= 0 and 1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the proportion of favorable outcome (mRS scores 0-2), % | through study completion, an average of 5 year | A favorable functional outcome define as mRS= 0-2. |
| incidence rates of all-cause and cardiovascular mortality, % | From date of randomization until the date of death from any cause, assessed up to 100 months | — |
| recurrent stroke/TIA | From date of randomization until the date of first documented recurrent stroke/TIA or date of death from any cause, whichever came first, assessed up to 100 months | — |
Countries
China
Outcome results
None listed